Stocktoria
Niagen Bioscience, Inc. NAGE
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products · website · IPO 2007-06-25
Niagen Bioscience, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 64.3% | 61.8% | 60.8% | 59.4% | 61.5% |
| Operating margin | 12.6% | 7.8% | -6.7% | -25.9% | -40.1% |
| Net margin | 13.4% | 8.6% | -5.9% | -23.0% | -40.2% |
| Return on assets | 16.3% | 12.5% | -9.0% | -30.6% | -46.9% |
| Return on equity | 22.7% | 18.5% | -17.4% | -57.7% | -85.5% |
| Current ratio | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 |
| Revenue growth | 29.9% | 19.2% | 16.0% | 6.8% | 13.8% |
Source: SEC EDGAR filings · CIK 0001386570 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.